Two new drug approvals to talk about (after I misplaced my notes!)

Antiandrogen withdrawal is an historically well described phenomenon where prostate cancer patients experience PSA responses AFTER stopping their anti-androgen. But does this happen with today's 2nd generation antiandrogens?

A plethora of recent updates:

-Pembrolizumab (perioperative) in head & neck cancer (Keynote-689)

-Prostate cancer updates on cabozantinib/atezolizumab (yes, really) and talazoparib

-Pirtobrutinib improves PFS in CLL

-Zanubrutinib has a new dosage form on the way

-Another mitomycin product approved with "reverse thermal properties"

-A new regimen for FL of tafasitamab/rituximab/lenalidomide

-A comparison of the new ROS1-inhibitor, taltrectenib, compared to other 1st-line treatment options

A recap of notable updates from ASCO 2025

1. Destiny-Breast09

2. BREAKWATER

3. ATOMIC

4. Delphi-304

5. CM 816 OS update

6. C-POST

7. Matterhorn

Our Landmarks of OncoPharm series returns to discuss the CLEOPATRA study, which established docetaxel, trastuzumab, pertuzumab (THP) as a standard first-line regimen for metastatic HER2-amplified breast cancer.

If you've been struggling with how to talk to patients about ivermectin for cancer, then this podcast is for you.

1. Cancer misinformation on social media (Loeb, et al): https://doi.org/10.3322/caac.21857

2. Clinician communication with patients about cancer misinformation (Bylund, et al): https://doi.org/10.1200/OP.22.00526

Discussing recent FDA approvals of penpulimab, avutometenib, defactinib, and telisotuzumab vedotin.

A splashy large study and two small studies suggest IV Mg in pre-hydration fluids can decrease the risk of cisplatin kidney injury.

Gupta et al. JAMA Oncol (2025): doi:10.1001/jamaoncol.2025.0756

PRAGMATIC. ESMO Open (2022): https://doi.org/10.1016/j.esmoop.2021.100351

Yamamoto et al. Anticancer Res (2015): https://pubmed.ncbi.nlm.nih.gov/25862878/

This episode summarizes recent updates on:

Tumor infiltrating clonal hematopoiesis (TI-CH) and its apparent negative impact on solid tumors (https://www.nejm.org/doi/full/10.1056/NEJMoa2413361)

Updated dostarlimab data on MMRd use in rectal cancer and other solid tumors in the neoadjuvant (definitive?!?!) setting (https://www.nejm.org/doi/full/10.1056/NEJMoa2404512)

Phase 1 study of 7 + 3 + Venetoclax (https://doi.org/10.1182/blood.2024026700)

Zongertinib, a new HER2 TKI (https://www.nejm.org/doi/full/10.1056/NEJMoa2503704)

BRCA revision mutations may explain some of the limited benefit seen in long-term follow-up studies with PARP inhibitors.

Bibliography:

1: BRCA reversion mutations predict resistance. https://doi.org/10.1158/2159-8290.CD-18-0715

2: SOLO3 Final OS Data. https://doi.org/10.1200/JCO.24.00933

3: Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. https://doi.org/10.1016/j.ccell.2024.10.015